Penn Highlands State College Partners with SAFE-T System to Provide Support for Victims of Sexual Assault
'We are excited to partner with SAFE-T System to bring top quality sexual assault care to victims who seek help from our hospital,' said Sarah Lehman, RN, BSN, Director of Nursing for Penn Highlands State College. 'Having expert nurses available 24/7 to support our patients and staff is invaluable.'
SAFE-T System was launched with support from the Department of Justice, Office for Victims of Crime as a solution to enhance access to high quality sexual assault care in underserved communities. When someone presents at Penn Highlands State College after experiencing sexual violence, they will immediately have access to a board-certified sexual assault nurse examiner (SANE). SANEs have extensive experience in the provision of sexual assault care and thanks to SAFE-T System's specialized forensic telehealth technology, their expertise can be accessed in the Centre County region. Typically, access to SANEs with this level of training and experience is often limited to large urban sexual assault centers. However, the innovative partnership Penn Highlands State College shares with SAFE-T System makes it possible to have this expertise in this region. The SAFE-T System telehealth SANE (teleSANE) can see the live exam in progress ensuring best practices, proper evidence collection and a safe and supportive environment for the patient.
'The expert nurse appears on the screen where they can talk to and support both the onsite nurse and the patient,' said Sheridan Miyamoto, Assistant Professor of Nursing at Penn State and Director of the SAFE-T Center. 'This is a true partnership. Our goal is to make sure the on-site nurse feels supported and confident during the exam and that the patient knows that they are getting the best care possible.'
Sexual assault forensic examinations are free to patients and no cost is incurred for SAFE-T System telehealth support. Forensic examination services are available at Penn Highlands State College Emergency Department 24 hours a day, 7 days a week.
Attachment
Corinne G. Laboon Penn Highlands Healthcare 724-258-1339 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034)
New York, USA, July 21, 2025 (GLOBE NEWSWIRE) — Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight The dynamics of the cutaneous T-cell lymphoma market are anticipated to change owing to the improvement in research and development activities, increasing prevalence, and the rising geriatric population. Additionally, the expected launch of therapies such as HyBryte, PTX-100, Lacutamab, BMS-986369, ONO-4685, and others will also boost the CTCL market growth. DelveInsight's Cutaneous T-cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging cutaneous T-cell lymphoma drugs, market share of individual therapies, and current and forecasted cutaneous T-cell lymphoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Cutaneous T-cell Lymphoma Market Report According to DelveInsight's analysis, the market size for cutaneous T-cell lymphoma was found to be USD 995 million in the 7MM in 2024. in the 7MM in 2024. The United States accounted for the highest cutaneous T-cell lymphoma market size, approximately 70% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Among the 7MM, the US accounted for the highest number of cases of CTCL in 2024, with nearly 3,000 cases. These cases are anticipated to increase by 2034. cases. These cases are anticipated to increase by 2034. Prominent cutaneous T-cell lymphoma companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, and others, are actively working on innovative cutaneous T-cell lymphoma drugs. and others, are actively working on innovative cutaneous T-cell lymphoma drugs. Some of the key cutaneous T-cell lymphoma therapies in the pipeline include HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685 , and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market. , and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market. By 2034, among all the therapies in the late stage, the highest revenue is expected to be generated by POTELIGEO in the 7MM. in the 7MM. In May 2025, 4SC received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization. received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization. In March 2025, Prescient Therapeutics opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL. opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL. In February 2025, Citius Pharmaceuticals and its oncology-focused subsidiary, Citius Oncology, announced that LYMPHIR has been assigned a unique, permanent HCPCS J-code (J9161) by the CMS. The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. Discover which cutaneous T-cell lymphoma medications are expected to grab the market share @ Cutaneous T-cell Lymphoma Market Report Cutaneous T-cell Lymphoma Overview Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that begins in the skin, arising from T lymphocytes—a type of white blood cell that plays a key role in immune defense against infections and cancer. Unlike other lymphomas that typically originate in the lymph nodes or internal organs, CTCL starts in the skin, which itself functions as a major lymphoid organ. Although B-cell lymphomas are generally more common, T-cell lymphomas like CTCL are more frequently found in the skin. Diagnosing CTCL involves a comprehensive clinical evaluation, including a review of symptoms, physical examination, detailed medical history, and specialized diagnostic tests. These tests help identify the exact type and stage of the disease and guide treatment planning. Skin biopsies are a standard diagnostic tool, particularly because early CTCL can mimic benign skin disorders such as psoriasis. In many cases, multiple biopsies are needed to establish a definitive diagnosis due to the subtle and variable nature of early-stage CTCL. Cutaneous T-cell Lymphoma Epidemiology Segmentation The cutaneous T-cell lymphoma epidemiology section provides insights into the historical and current cutaneous T-cell lymphoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of CTCL Type-specific Cases of CTCL Gender-specific Cases of CTCL Stage-specific Cases of CTCL Treatment-eligible Pool in Early and Advanced Stages of CTCL Download the report to understand which factors are driving cutaneous T-cell lymphoma epidemiology trends @ Cutaneous T-cell Lymphoma Treatment Algorithm Cutaneous T-cell Lymphoma Treatment Market The treatment strategy for mycosis fungoides and Sézary syndrome, both forms of cutaneous T-cell lymphoma, varies depending on the extent of skin involvement and whether the disease has spread. Mycosis fungoides typically responds well to therapies directed at the skin or the whole body, whereas Sézary syndrome usually necessitates systemic treatment approaches. VALCHLOR (mechlorethamine) is the first and only FDA-approved topical formulation of mechlorethamine for patients with Stage IA or IB mycosis fungoides-type CTCL who have previously undergone skin-directed therapy. For patients with early-stage disease, topical corticosteroids are considered the first-line treatment. Additionally, topical Toll-like Receptor (TLR) agonists, which stimulate local production of interferons and cytokines to promote tumor cell death and enhance the immune response, have shown clinical benefit in managing limited-stage mycosis fungoides. In cases of advanced-stage mycosis fungoides or Sézary syndrome, a comprehensive and multidisciplinary approach is required. Management often involves combinations of skin-directed therapies, immune-modulating agents, and sequential systemic chemotherapy. However, for early-stage disease, multi-agent chemotherapy is generally avoided. Instead, a risk- and stage-adapted strategy, aligned with the National Comprehensive Cancer Network (NCCN) Guidelines, is typically used. This includes the use of biologic-response modifiers (such as bexarotene and interferon-alpha), histone deacetylase (HDAC) inhibitors (like romidepsin), or targeted therapies such as monoclonal antibodies or antibody-drug conjugates (e.g., mogamulizumab, brentuximab vedotin). Treatment choices are tailored to each patient, taking into account factors such as age, overall health, disease stage and burden, progression rate, and prior treatments. For advanced-stage CTCL (Stages IIB–IV), effective systemic therapies include HDAC inhibitors such as ISTODAX (romidepsin) and ZOLINZA (vorinostat). Notably, vorinostat was the first HDAC inhibitor to gain FDA approval in 2006 for treating progressive, persistent, or relapsing CTCL. Learn more about the cutaneous T-cell lymphoma treatment options @ Cutaneous T-cell Lymphoma Treatment Guidelines Cutaneous T-cell Lymphoma Emerging Drugs and Companies Some of the drugs in the pipeline include HyBryte (Soligenix and Sterling Pharma Solutions), PTX-100 (Prescient Therapeutics), Lacutamab (Innate Pharma), Golcadomide (Bristol Myers Squibb), and others. HyBryte is a topical formulation containing hypericin, one of the most light-sensitive compounds known. The product has been granted both Orphan Drug Designation and Fast Track Designation by the U.S. FDA, along with orphan status from the European Medicines Agency (EMA). Soligenix showcased new clinical data supporting HyBryte's use in treating cutaneous T-cell lymphoma at two major events: the United States Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting held from March 7 to 11, 2025. In an April 2024 press release, the company stated it expects to report top-line results from its 18-week confirmatory FLASH2 study, being conducted in both the U.S. and Europe, during the second half of 2026. PTX-100 is a novel, first-in-class agent that inhibits a key enzyme involved in cancer progression by targeting the oncogenic Ras signaling pathway. The drug is currently undergoing a Phase IIa trial in patients with relapsed or refractory CTCL, with potential progression to a Phase IIb registration study. As outlined in Prescient Therapeutics' May 2025 investor update, the company expects to receive Orphan Drug Designation in Europe by Q3 2025. Additionally, an interim review of Phase IIa trial data is planned for Q4 2025 or early 2026. Prescient also announced in May 2025 that the first patient had been successfully dosed in this ongoing Phase IIa study. Lacutamab is a humanized, first-in-class antibody targeting KIR3DL2, designed to induce cytotoxicity. It is being tested in an open-label, multicohort Phase II study in CTCL and another Phase II study in peripheral T-cell lymphoma (PTCL). According to Innate Pharma's most recent annual update from May 2025, the company aims to begin a Phase III trial of lacutamab, with plans to pursue accelerated approval by 2027. Furthermore, long-term follow-up data from the TELLOMAK Phase II trial, focusing on patients with Sézary syndrome and mycosis fungoides, will be presented at the 2025 ASCO Annual Meeting on June 2 in Chicago, Illinois. The anticipated launch of these emerging cutaneous T-cell lymphoma therapies are poised to transform the cutaneous T-cell lymphoma market landscape in the coming years. As these cutting-edge cutaneous T-cell lymphoma therapies continue to mature and gain regulatory approval, they are expected to reshape the cutaneous T-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for cutaneous T-cell lymphoma, visit @ Cutaneous T-cell Lymphoma Management Cutaneous T-cell Lymphoma Market Dynamics The cutaneous T-cell lymphoma market dynamics are anticipated to change in the coming years. The prognosis for most patients with CTCL is promising, especially with early detection and timely treatment, which can enable decades of survival with ongoing care. However, the disease's heterogeneity and involvement of multiple pathways create a strong foundation for the development of diverse targeted therapies. Emerging evidence supporting PTX-100's superior efficacy and safety over LYMPHIR further underscores the potential of targeting GGT1 inhibition. Combined with the limited pipeline activity in CTCL, this presents a significant opportunity for drug developers to innovate and bring novel therapies to an underserved market. Furthermore, many potential therapies are being investigated for the treatment of cutaneous T-cell lymphoma, and it is safe to predict that the treatment space will significantly impact the cutaneous T-cell lymphoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the cutaneous T-cell lymphoma market in the 7MM. However, several factors may impede the growth of the cutaneous T-cell lymphoma market. The diagnosis and treatment of cutaneous T-cell lymphoma remain challenging due to several factors: multiple biopsies are often required for a definitive diagnosis, potentially delaying appropriate treatment; the underlying mechanisms driving CTCL-associated pruritus are still poorly understood despite advances in research; targeted therapies frequently face issues of limited tolerance and efficacy, leading to discontinuation from toxicity or resistance; and the recent negative opinion and discontinuation of KINSELBY underscore regulatory risks, casting uncertainty over the future development of similar therapies. Moreover, cutaneous T-cell lymphoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cutaneous T-cell lymphoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cutaneous T-cell lymphoma market growth. Cutaneous T-cell Lymphoma Report Metrics Details Study Period 2020–2034 Cutaneous T-cell Lymphoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Cutaneous T-cell Lymphoma Market CAGR 7.1% Cutaneous T-cell Lymphoma Market Size in 2024 USD 995 Million Key Cutaneous T-cell Lymphoma Companies Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, Kyowa Hakko Kirin, Pfizer (Seagen), Takeda, Helsinn Therapeutics, Citius Pharmaceuticals, Valeant Pharmaceuticals, Bausch Health, and others Key Cutaneous T-cell Lymphoma Therapies HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685, POTELIGEO, ADCETRIS, VALCHLOR/LEDAGA, LYMPHIR, TARGRETIN, ISTODAX, and others Scope of the Cutaneous T-cell Lymphoma Market Report Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies Cutaneous T-cell Lymphoma current marketed and emerging therapies Cutaneous T-cell Lymphoma Market Dynamics: Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cutaneous T-cell Lymphoma Market Access and Reimbursement Discover more about cutaneous T-cell lymphoma drugs in development @ Cutaneous T-cell Lymphoma Clinical Trials Table of Contents 1 Key Insights 2 CTCL Market Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 CTCL Market Overview at a Glance 7 Disease Background and Overview 8 CTCL Treatment 8.1 Treatment of Limited-stage Mycosis Fungoides/Sézary Syndrome 8.2 Treatment of Advanced-stage Mycosis Fungoides/Sezary Syndrome 8.3 CTCL Treatment Guidelines 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale 9.3 Total Incident Cases of CTCL in the 7MM 9.4 The United States 9.5 EU4 and the UK 9.6 Japan 10 Patient Journey 11 CTCL Marketed Drugs 11.1 Key Competitors 11.2 POTELIGEO (mogamulizumab): Kyowa Hakko Kirin 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Clinical Development 11.2.4.1 Clinical Trial Information 11.2.5 Safety and Efficacy 11.2.6 Analyst Views 11.3 ADCETRIS (brentuximab vedotin): Pfizer (Seagen) and Takeda 11.4 VALCHLOR/LEDAGA (mechlorethamine): Helsinn Therapeutics 11.5 LYMPHIR/REMITORO/E7777/ONTAK (denileukin diftitox): Citius Pharmaceuticals 12 Discontinued Therapy 12.1 KINSELBY (resminostat): 4SC 12.1.1 Product Description 12.1.2 Other Developmental Activities 12.1.3 Clinical Development 12.1.3.1 Clinical Trials Information 12.1.4 Safety and Efficacy 12.1.5 Analyst Views 13 CTCL Emerging Therapies 13.1 Key Cross Competition 13.2 HyBryte (Synthetic Hypericin/SGX301): Soligenix and Sterling Pharma Solutions 13.2.1 Product Description 13.2.2 Other Developmental Activities 13.2.3 Clinical Development 13.2.3.1 Clinical Trials Information 13.2.4 Safety and Efficacy 13.2.5 Analyst Views 13.3 PTX-100: Prescient Therapeutics 13.4 Lacutamab (IPH4102): Innate Pharma 14 CTCL: Seven Major Market Analysis 14.1 Key Findings 14.2 Market Outlook 14.3 Conjoint Analysis 14.4 Key Market Forecast Assumptions 14.4.1 Cost Assumptions and Rebate 14.4.2 Pricing Trends 14.4.3 Analogue Assessment 14.4.4 Launch Year and Therapy Uptake 14.5 Total Market Size of CTCL in the 7MM 14.6 The United States Market Size 14.7 EU4 and the UK Market Size 14.8 Japan 15 Unmet Needs 16 SWOT Analysis 17 KOL Views 18 CTCL Market Access and Reimbursement 18.1 United States 18.2 EU4 and the UK 18.3 Japan 18.4 Market Access and Reimbursement of CTCL 19 Bibliography 20 Report Methodology Related Reports Cutaneous T-cell Lymphoma Pipeline Cutaneous T-cell Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CTCL companies, including Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc., among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Non-Hodgkin's Lymphoma Pipeline Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others. Peripheral T-Cell Lymphoma Market Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Hamilton Spectator
6 hours ago
- Hamilton Spectator
REPEAT – Health care advocates afraid of major cuts and privatization hold shadow summit and rally at Council of the Federation next week
HUNTSVILLE, Ontario, July 21, 2025 (GLOBE NEWSWIRE) — Outside the Council of the Federation and the gathering of First Ministers, public health care advocates from across Canada will be joining a shadow summit, rally, and car cavalcade. Attendees include Health Coalitions, patients, patient advocates, nurses, doctors, care workers, mental health advocacy organizations, environmental groups, Indigenous organizations, seniors' groups, union leaders, and more. When & Where: Shadow Summit – Monday, July 21 from 10 a.m. to 4:30 p.m. Hidden Valley Resort (next door to the Deerhurst Resort where the Premiers are meeting) 1755 Valley Rd, Huntsville, ON P1H 1A8 Reporters & health care reporters welcome. Opening plenary re key issues & updates across Canada, 10:30 – 11:30 a.m. Rally and Car Cavalcade – Tuesday, July 22 Who: hosted by the Canadian Health Coalition, Ontario Health Coalition, and the Ontario Federation of Labour. As Canada's leaders meet, our public health care system is, without exaggeration, in open crisis. Runaway privatization is taking funding and staff away from public health care services. Staffing shortages are a national catastrophe, forcing emergency departments to close and leaving health care workers with impossible workloads while patients wait longer and suffer more. Private clinics are violating the Canada Health Act, charging patients hundreds to thousands of dollars for surgeries and diagnostic tests in illegal user fees and extra-billing. Seniors can't access the care they need. Mental health and addiction services are underfunded, subject to privatization and cuts, or simply unavailable. Millions still do not have access to family medicine. The implementation of the first phase of pharmacare has stalled. This event serves to remind our political leaders that the economy exists to serve people, not the other way around, and the economy is more than militarism and private sector projects. If a 70-year-old goes to a private clinic and is forced to use their life savings and pay thousands of dollars for their surgery, what chance do they have to get out of poverty for the rest of their life? If a person has diabetes and cannot afford their insulin and supplies, what economy is there for them? Health care can't wait, and privatization is the destruction of Public Medicare, not a solution. Health Coalitions are demanding funding, resources, and public solutions in the public interest. For more information: Natalie Mehra, executive director, Ontario Health Coalition cell (416) 230-6402; Salah Shadir, administration & operations director, Ontario Health Coalition cell (647) 648-5706.
News24
8 hours ago
- News24
After US funding cuts, Mozambican children died: Who bears responsibility?
After the US Agency for International Development (USAID) abruptly terminated billions of dollars' worth of overseas aid grants, the health system in central Mozambique was left in tatters. Earlier this year, I travelled to two badly hit provinces of the country to describe the toll. In one article, I reported how thousands of orphaned and vulnerable children in Sofala province had been abandoned by their USAID-funded case workers. Many of these children are HIV-positive and had relied on case workers to bring them their medicines or accompany them to hospitals. Without them, some children stopped taking their treatment and died. In a second piece, I reported how USAID had cut funding for contractors transporting medicines and diagnostic tests to health facilities in Manica province. This led to shortages of HIV drugs at hospitals in the area, which also led to the deaths of children. In the midst of all this chaos, I was often curious to know from people on the ground who they held accountable for this situation and who they believed needed to solve the problem. My assumption was that they would call for the Mozambican government to help them out. I was surprised to find that in the affected villages which I visited, this was far from anyone's expectation. In fact, for most it was simply unthinkable that their government could do anything to save them. 'You mentioned the government,' one community leader said after I asked whether the state should intervene. 'But even these chairs we're sitting on are stamped with USAID logos. So what help can we expect from the government?' Indeed, the more I learned about governance in Mozambique, the more understandable this attitude became. Throughout the country, core government functions have been outsourced to a combination of foreign governments, aid agencies, interstate bodies, and private companies. For instance, many of the country's essential medicines are procured by a large international financing body called the Global Fund to Fight Aids, Tuberculosis and Malaria. Up until January, the transportation of these medicines to hospitals was overwhelmingly financed by US aid agencies, as were the pay cheques of many health workers. Outside of the healthcare sector, the story is similar. The main highway that I travelled along to reach different villages was built and paid for by Chinese corporations and banks. To keep hydrated I relied on bottled water supplied by private companies since the taps either didn't run or produced contaminated water. In many of the impoverished rural settlements that I visited, there was virtually no state infrastructure, and people received no financial support from the government. Instead, they primarily depended on aid organisations. The country's national budget has historically been heavily supplemented by foreign bodies, including the International Monetary Fund (IMF) and European Union. (Though much of this support was suspended in 2016/2017.) Even national defence has been partially outsourced. When Islamist militants began rampaging through the northern province of Cabo Delgado, the government struggled to contain it and contracted Russian and South African mercenary groups. When that failed, they authorised a military intervention by the Southern African Development Community (SADC) and invited a parallel mission by the Rwanda Defence Forces. It is thus no surprise that Mozambicans have virtually no expectation that their own government will come to the rescue when facing an emergency. Instead, they look outward. As one community leader in a rural village told me, 'Here, we depend on Trump.' Cash-strapped and corrupt Mozambique has 35 million people. About 2.5 million live with HIV, the second highest HIV-positive population in the world after South Africa. Life expectancy is well under 60. The country is extremely poor: eight in ten people live on less than three dollars per day. The government is also deeply cash-strapped. The South African government spends 10 times more per citizen than the Mozambican government does. A large chunk of its spending goes towards paying off debt. At present, Mozambique simply doesn't have the money to build an effective health system, though had it spent its limited budget reserves more effectively over the years it could have developed a health system that was at least a bit more independent of donor support. Instead, the country's budgetary resources have often been wasted on corruption. Mozambique currently ranks 146th out of 180 in the world on Transparency International's Corruption Perceptions Index. This has directly played a role in its public health woes. One clear example of this is the Tuna Bonds scandal, in which state-owned companies took out two billion dollars' worth of loans, backed by secret state guarantees. This was supposedly to finance large fishing and maritime security projects. In reality, much of the money was siphoned off to enrich political elites, including the then-finance minister (who is now in prison). As a result of those decisions, the country was swallowed by debt. And when the extent of the corruption was publicised in 2016, the IMF pulled its financial support for Mozambique. A detailed 2021 report found this directly led to a fall in economic growth and government spending. It states: 'Comparing the three-year average of 2016-18 to the three previous years, spending on health and education fell by USD 1.7 billion – entirely due to the debt.' The country's governance crisis is further demonstrated by the political unrest that engulfed the country after the October elections last year, triggered by accusations of election fraud. The accusations were likely overblown, but international observers said the election was not free and fair. Even during the brief one-week period that I spent in central Mozambique, signs of corruption and mismanagement filtered into my interactions with officials. For instance, before I embarked on a multi-day tour of one province, government officials told me that someone from the provincial health department would need to accompany me on my trip. This was apparently in order to make formal introductions to district-level officials that I hadn't asked to meet. For this apparently vital service, the man would need to be paid a per diem of roughly 500 rand a day for two days, they said. The civil servant in question was a very senior person in the provincial health department. Despite facing a collapsing health system in the wake of the US cuts, he was apparently ready to drop everything he had going for the rest of that week to follow me around. READ | US cancels 83% of USAID programmes, impacting global aid efforts When I explained that I wouldn't pay a government official to stalk me, I was told that saying no wasn't an option. This is unfortunately the way things are done around these parts, said a local who helped arrange the tour. (Neither GroundUp, Spotlight nor I paid the bribe, incidentally.) US responsibility Against this backdrop, it is perhaps no surprise that defenders of the current US government have often resorted to arguments about moral responsibility when justifying the decision to abruptly slash aid. It is reasonable to ask why the American taxpayer should bear any of the brunt of Mozambique's public health system when so many of its problems have been caused by the Mozambican government itself. But it's not so simple. The Mozambican civil war from 1977 to 1992 destroyed the country. The anti-communist RENAMO insurgency likely received millions of dollars of support from US evangelists, despite committing numerous atrocities. It is strongly suspected that the US government also materially supported RENAMO. So the US's involvement in Mozambique has not been innocent. It could be argued that its aid spending was the least the US could do to make amends for its role in the war. Moreover, Mozambique didn't develop its high level of dependency in isolation. For over two decades, the US actively took responsibility for core functions of the country's health system. Up until January, the US government continued to sign numerous contracts with local organisations, pledging millions of dollars to help run life-saving health programmes for years into the future. The health system was consequently built around these commitments. If the US was going to take that much responsibility for the wellbeing of some of the world's most vulnerable people, then it had a duty to at least provide notice before pulling the plug. Instead, it chose to slash the funds instantly, and in a manner that needlessly maximised damage and confusion. Stop-work orders were issued overnight which required that people who were doing life-saving work down their tools immediately. Organisations decided to adhere to these instructions rigidly in the hope that their funding would be reinstated. At that point the Trump administration said it was only pausing aid funding pending a review, and no one wanted to give the reviewers a reason to terminate their programmes. The consequence was complete chaos. Orphaned children in extremely rural parts of Mozambique waited for their case workers to bring them their medicines, but often they simply never came. Many of these children had no idea why they had been abandoned. When certain case workers decided to defy the stop-work order and continue their work voluntarily, they were forced to do so in secret. To add fuel to the fire, the Trump administration routinely provided contradictory information to its former recipients and to the public. The initial executive order signed in January said all foreign development assistance would be suspended for 90 days, pending a review, and might be restored after this time. Then, Secretary of State Marco Rubio issued a waiver which stated that the suspension wouldn't apply to life-saving humanitarian services. Rubio told the public that organisations providing these life-saving services could instantly resume their work under this order. Yet the organisations themselves received different instructions from their USAID officers. Rather than immediately continuing their work, they were told to submit revised budgets that only covered life-saving services and to wait for approval. Organisations rushed to submit these budgets by the deadline. But in the end, the green light never came and their funds remained frozen. This was not only the case in Mozambique; researchers estimated that virtually no funds were released under Rubio's waiver globally. In the meantime, Rubio stated that organisations that hadn't resumed life-saving activities were clearly unable to understand instructions or were simply trying to make a political point. Later on, the organisations received explicit termination notices, ending their programmes. Despite this, US embassies and several large media outlets continued to reference Rubio's order as if it was actually implemented en masse. Even as I write this, the on-again, off-again US aid story is unfinished. This mixed messaging created an enormous amount of confusion for staff of these organisations and the recipients of their work, ultimately for no clear benefit to the American people. There was simply never any reason to act this callously toward health organisations to whom USAID had pledged its support. In contrast to the rampant corruption which has plagued the Mozambican government, these organisations were heavily audited in order to continue receiving funding. The work they were doing was clearly making a material difference to some of the poorest people on earth. In the far-flung settlements that I visited, villagers told me about how their lives had been transformed by these organisations. Many were only put on life-saving HIV treatment because of them. Whatever arguments one may want to advance about the importance of self-sufficiency and national responsibility, none of this justifies the US government administering the aid cuts in such a callous and confusing manner.
